Summarizing some things before Monday, Sep 9, when BSDM will be presenting at this investor’s conference:
15th Annual Rodman & Renshaw Global Investment Conference
9/9/13 10:00 am - 11:00 am EDT
Also, Terumo will be promoting and demonstrating the MTX-180 at the CIRSE conference on Sep 14th thru the 18th. Terumo is strongly touting the MicrothermX because they have a major plan to expand their Interventional Oncology (IO) offerings and they expect the MTX-180 (microwave ablation, MWA) to have a major impact. This expectation is supported by a) a quite sizable number of very positive comparative trials that show this product to be much superior to the present leading IO product (Radio Frequency Ablation, RFA) and b) Terhumo’s own in-depth evaluations between the MTX-180 and various competing equipment. Also, the present world market for IO equipment is rapidly approaching $3 Billion (I think RFA now has something like 40% of the IO market). Further, IO practice has been growing at something like 20% per year. Presumably, the major advance in IO afforded by the MTX-180 will increase this growth. (The present Terumo efforts are in about 40% of the whole world’s IO market – and BSDM is pursuing other major distributors, for whole-world coverage; perhaps servicing some areas themselves).
Of Note: With recognition of the outstanding performance of the MTX-180, it stands to reason that much of the IO growth will soon accrue to this product! And, Terhumo “has the chops” to well promote the MTX-180! BSDM surely has intent, at the Global Investment Conference on the 9th, to point to the upcoming CIRSE activities. This should generate significant new-investor attention towards the CIRSE Conference (BSDM’s NR re this conference follows).
http://finance.yahoo.com/news/terumo-showcase-bsds-microthermx-microwave-131500459.html
Terumo to Showcase BSD's MicroThermX® Microwave Ablation System at CIRSE – World's Largest Interventional Radiology Conference
• Over 6,000 medical professionals from 85 countries attend CIRSE
• Terumo sponsoring focused training sessions for all Terumo sales representatives to capitalize on MicroThermX sales during the conference
• Terumo is placing MicroThermX systems with key physician opinion leaders throughout Europe
• Some of the world's leading experts in ablation will give presentations on MicroThermX
SALT LAKE CITY--(BUSINESS WIRE)--
BSD Medical Corporation (BSDM) (the “Company” or “BSD”) announced today that Terumo Europe NV (Terumo), a wholly owned subsidiary of Terumo Corporation, will showcase BSD's MicroThermX® Microwave Ablation System (MicroThermX) at the annual Cardiovascular and Interventional Radiological Society of Europe (CIRSE) conference. CIRSE, which will be held in Barcelona, Spain, on September 14-18, 2013, is the world's largest and most prestigious conference in the field of minimally invasive image-guided therapies. In preparation for CIRSE, Terumo is sponsoring focused training sessions for all Terumo sales representatives to ensure they are prepared to capitalize on MicroThermX sales during the conference. As part of the overall sales strategy for the conference, Terumo is placing MicroThermX systems with key physician opinion leaders throughout Europe. Terumo will also send MicroThermX promotional material to all conference attendees. Over 6,000 medical professionals from 85 countries attend CIRSE, reflecting the global impact of the rapidly expanding field of interventional radiology.
Terumo is also sponsoring a symposium at CIRSE highlighting the advantages of the MicroThermX. The symposium will feature three presentations focused solely on MicroThermX. "Microwave for lung tumour ablation: potential advantages compared with radiofrequency ablation and clinical settings" will be presented by Professor Philippe Pereira. "Microwave for liver tumour ablation: potential advantages compared with radiofrequency ablation and clinical settings" will be presented by Dr. Laura Crocetti. "Lessons from Microwave ablation with MicroThermX™: why, when, where and how" will be presented by Dr. Damian Dupuy. Professor Pereira and Drs. Crocetti and Dupuy are leading experts in the field of interventional oncology.
"We are excited to announce that Terumo will focus on the MicroThermX at CIRSE, the largest interventional oncology conference in the world. Terumo's aggressive marketing strategy should allow them to capture a significant share of the rapidly growing interventional oncology market," said Harold Wolcott, BSD President and CEO. "BSD’s exclusive distribution agreement with Terumo Europe NV for 100 countries represents one of the most significant milestones in our corporate history. The potential market size for thermal ablation in these countries is estimated to be in excess of $1 billion in annual sales."
About Terumo Corporation
A world leader in state-of-the-art medical devices and interventional oncology, Tokyo-based Terumo Corporation (TYO: JP:4543) reported 2013 sales of nearly $5 billion and has a market cap in excess of $8 billion. Through the sale and promotion of a high quality line of devices used for tumor embolization, the closing or blocking of blood vessels, Terumo Europe NV has established itself as a pioneer in the field of interventional oncology.
About the MicroThermX® Microwave Ablation System
The MicroThermX is a compact, mobile, state-of-the-art, proprietary system that includes a microwave generator, single-patient-use disposable antennas, and a thermistor-based temperature monitoring system. The innovative design of the MicroThermX is the first of its kind that allows delivery of higher power levels using a single generator. The MicroThermX utilizes innovative synchronous phased array technology that was developed and patented by BSD to provide a wide range of uniform zones of ablation. The MicroThermX includes innovative, high-end disposables (SynchroWave antennas) that are used in each ablation treatment and will provide a significant ongoing revenue stream. The soft tissue (tumor) ablation world market potential is estimated to exceed $2.3 billion. The U.S. Food and Drug Administration (FDA) has granted the Company a 510(k) clearance to market the MicroThermX for ablation of soft tissue. BSD has also received CE Marking for the MicroThermX System, which allows BSD to market the MicroThermX in Europe. CE Marking is also recognized in many countries outside of the EU, providing BSD the ability to market the MicroThermX to a number of international markets. |
